- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00787007
Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers
Randomized, Double-Blind, Single Rising Dose Study of S-equol in Normal Volunteers
Study Overview
Detailed Description
The study is a double blind, randomized, placebo-controlled, dose-escalation study of the safety and tolerability of single doses of S-equol up to 320 mg in healthy male and female adult subjects. Approximately 8 qualified volunteers will be selected at each dose level and randomly assigned to receive S-equol or placebo, in the fasted state. For the 20 mg dose group, subjects will complete two treatment periods, one in the fasted state, and one in the fed state.
A safety review of study results for each dose group will occur when Day 8 follow-up visit safety data are available, and prior to enrollment/dosing of the next subsequent dose group. Given favorable safety review of a dose group's experience, the subsequent dose group will be enrolled/dosed at least 10 days after the previous group's dosing.
Pharmacokinetic evaluations consist of determination of plasma and urine concentrations of free and total conjugated S-equol at various time points. Safety evaluations include physical examination,vital signs, ECG, serum chemistry, hematology, and urinalysis, 12-lead telemetry, and assessment of clinical signs and symptoms.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Washington
-
Tacoma, Washington, United States, 98418
- Charles River
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male and female volunteers aged 18 to 65 years, inclusive
- Female subjects must be non-pregnant and non-lactating; surgically sterile, post-menopausal or be using an acceptable non-hormonal method of birth control
- Must not have used any hormonal agents or devices within 4 weeks prior to enrollment
- In good health as determined by a physician
- BMI between 18 and 30, inclusive
- Normal clinical laboratory test results
- Negative drug and alcohol toxicology screens
- Negative HIV antibody and hepatitis panel screening results
- For men over 44 years of age, PSA ≤ 2.0 ng/mL
- For women over 44 years of age, normal mammography and pelvic ultrasound
- Protein C and Protein S activity levels above the lower limit of normal
- Negative for Factor V Leiden.
Exclusion Criteria:
- History of any chronic, subacute or acute condition of clinical significance
- Total bilirubin level >0.9, conjugated bilirubin >0.4, or unconjugated bilirubin >0.8
- Fasting cholesterol level >280 mg/dL; fasting triglyceride level >1.5 x ULN
- History of thromboembolic events or estrogen-dependent benign or malignant neoplasm
- Resting systolic blood pressure >140 mm Hg or <90 mm Hg, or diastolic blood pressure >90 mm Hg or <60 mm Hg
- Resting pulse >100 beats/minute or <45 beats/minute
- Abnormal 12-lead ECG or telemetry results
- Subject is unwilling or unable to comply with study rules
- History of sudden cardiac death in the immediate family, or a personal history of cardiac disease, treated hypertension, congestive heart failure, or unexplained syncope
- History of cancer, other than basal cell carcinoma or stage 1 squamous cell carcinoma, that has not been successfully treated
- Use of any prescription or over-the-counter medication within 1 week prior to Day -1 or anticipates the need for any medication during the course of the study
- History or intolerance to estrogen medication
- History of substance abuse, drug addiction, or alcoholism within 3 years
- Inability to abstain from alcohol, caffeine, Yerba mate tea, or from grapefruit, grapefruit juice or flavonoid-rich foods from 48 hours prior to the administration of study medication and throughout the duration of the study.
- History of smoking or any use of a tobacco or nicotine containing product within 6 months
- Donated blood or blood products within 30 days
- Mental instability or inability to be compliant with the protocol
- Subject has received an investigational test substance within 60 days or anticipates receiving any investigational test substance other than S-equol during the course of this study
- Subject has been previously enrolled in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
10 mg
|
capsule, oral, single dose
Other Names:
|
EXPERIMENTAL: 2
20 mg, fasted and fed
|
capsule, oral, single dose
Other Names:
|
EXPERIMENTAL: 3
40 mg
|
capsule, oral, single dose
Other Names:
|
EXPERIMENTAL: 4
80 mg
|
capsule, oral, single dose
Other Names:
|
EXPERIMENTAL: 5
160 mg
|
capsule, oral, single dose
Other Names:
|
EXPERIMENTAL: 6
320 mg
|
capsule, oral, single dose
Other Names:
|
PLACEBO_COMPARATOR: 7
placebo capsule
|
capsule, oral, single dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the safety and tolerability of ascending, single oral doses of S-equol, administered in fasted and fed states, in healthy male and female volunteers.
Time Frame: Continuous
|
Continuous
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the single dose pK profile of S-equol in the fed and fasted state. To compare the pK profiles of younger and older and male and female volunteers.
Time Frame: Variable
|
Variable
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AUS-CT01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on S-equol
-
Ausio Pharmaceuticals, LLCCompleted
-
University of Colorado, DenverRecruitingChronic Kidney DiseasesUnited States
-
The University of Texas Health Science Center at...Completed
-
Akira SekikawaNational Institute on Aging (NIA)RecruitingCognitive Decline | Arterial Stiffness | White Matter LesionsUnited States
-
Ausio Pharmaceuticals, LLCCompletedMenopauseUnited States, Australia
-
Pharmavite LLCBiofortis, Merieux NutriSciencesCompleted
-
Russell SwerdlowAusio Pharmaceuticals, LLCCompleted
-
Ausio Pharmaceuticals, LLCCompletedBenign Prostatic HyperplasiaUnited States, India
-
Russell Swerdlow, MDAusio Pharmaceuticals, LLCCompleted
-
Chinese University of Hong KongUnknown